-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1211 Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia

Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Translational Research, Clinical Research, health disparities research
Saturday, December 9, 2023, 5:30 PM-7:30 PM

Elena Monzón Manzano, PhD1,2*, Maria Teresa Álvarez-Roman1,2,3*, Paula Acuña1,2*, Elena G Arias-Salgado, PhD1,2*, Raquel Ramírez Martín, MD2,4*, Maria Cristina Pascual Izquierdo, MD, PhD5*, Maria Isabel Rivas Pollmar, PhD, MD1,2*, Monica Martin Salces, PhD, MD1,2*, Waleed Ghanima, MD, PhD6,7,8, Víctor Jiménez-Yuste, MD, PhD1,2,3* and Nora Butta, PhD2,9*

1Department of Haematology, Hospital Universitario La Paz, Madrid, Spain
2IdiPAZ, Madrid, Spain
3Faculty of Medicine, Universidad Autonoma de Madrid, Madrid, Spain
4Department of Geriatrics, Hospital Universitario La Paz, Madrid, Spain
5Servicio de Hematología, Hospital Universitario Gregorio Marañón, Instituto de Investigación Gregorio Marañón, Madrid, Madrid, ESP
6Østfold Hospital, Gralum, Norway
7Østfold Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
8Østfold Hospital, Gralum, NOR
9Hospital Universitario La Paz, Madrid, Madrid, Spain


Incidence of primary immune thrombocytopenia (ITP) has two peaks: one in children and young adult and one in the elderly. Management of older patients represents a challenge, because older age is associated with increased frailty, comorbidities, polypharmacy, and worse outcome. Moreover, we cannot rule out the effect of old age on hemostasis of individuals without ITP.


We aimed to compare characteristics of hemostasis in healthy controls and in patients with ITP stratified according to their age in ≤65 years old (yo) and >65 yo, in order to determine if old age modifies hemostasis and if there is an increased risk of bleeding in older patients with ITP.


This is a prospective project that was approved by the Ethics Committee from Hospital Universitario La Paz. Informed consent was signed before sampling. ITP patients (n=100≤65 yo and n=68>65 yo) and healthy controls (n=100≤65 yo and n=28>65 yo) were recruited.

Patients with ITP and participants with uncontrolled hypertension, artery disease, abnormal hepatic or renal function tests, a diagnosis of a bleeding disorder or thrombopathy, treatment with drugs that could affect hemostasis or a history of thrombotic episodes were excluded.

We evaluated platelet activation markers (TRAP and ADP-induced activation of fibrinogen receptor determined through PAC1-binding, and TRAP-induced P-selectin exposure with anti-P-selectin antibody); active caspase-3, -7, -8 and -9; surface loss of sialic acid determined by the binding of Ricinus Communis Agglutinin I (RCA) to galactose residues; and presence of GlcNAc residues on platelet’s surface determined by the binding of Wheat Germ Agglutinin (WGA). Neuraminidase 1 (NEU1) associated to membrane of quiescent platelets were tested with anti-NEU1-Alexa546 antibody. All samples were analyzed by flow cytometry.

Thrombin generation was measured in platelet-poor plasma by Calibrated automated thrombogram (CAT) and coagulation was triggered by proper recalcification and the addition (final concentrations) of 1 pmol/l of recombinant human tissue factor and 4 µmol/l of phospholipid mixture (PPP-Reagent LOW). The following parameters were measured: Lagtime (= time when 10 nmol/l thrombin is formed); peak height (PH = maximum thrombin concentration reached); and endogenous thrombin potential (ETP = area under the thrombin-concentration-vs-time curve) were calculated with the Thrombinoscope software package (Thrombinoscope BV).

Statistical analyses were performed with GraphPrism 6.0. Comparisons between controls vs ITP patients with similar range of age; controls ≤65 vs >65 yo; and ITP patients ≤65 vs >65 yo were performed with 2 way ANOVA and p<0.05 were considered as significant.


Table 1 shows results obtained. There was no difference in age between controls and ITP groups with the same age range. Platelets from patients with ITP had a low ability to be activated when compared to their corresponding control group, and impairment in activation of fibrinogen receptor was even more evident for the older group of ITP patients.This fact was not due to a reduction in the number of fibrinogen receptors. Caspases 3, 8 and 9 were higher in ITP patients than their age-matched controls. Moreover, caspase 3 was higher in older ITP than in patients ≤65 yo.

Regarding analyses of glycoside residues, platelets from patients with ITP had less sialic acid and more GlcNAc residues on their surface when compared with the corresponding controls. Surprisingly, sialic content in platelets from controls > 65yo was higher than in the controls ≤65 yo, and this fact is in accordance to the lowest content of NEU1 associated to their membrane.

Plasma from ITP patients had a higher capacity to generate thrombin when compared with their age-matched control group. Nevertheless, both groups (control and ITP)> 65 yo generated less thrombin than the groups ≤65 yo. No differences were observed in other CAT parameters.


Platelets from patients with ITP are less functional than those from control groups. This impairment seemed to be more pronounced in platelets from patients >65 yo, putting forward the possibility of an increased risk of bleeding in older patients with ITP. This study also demonstrates that old age might modify hemostasis even in individuals without ITP.

Work supported by Instituto de Salud Carlos III (ISCIII) (PI19/00772, PI22/01489), co-funded by the European Union.

Disclosures: Álvarez-Roman: Grifols: Honoraria, Speakers Bureau; Roche: Honoraria, Speakers Bureau; Amgen: Honoraria, Speakers Bureau; LFB: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Novo Nordisk: Honoraria, Speakers Bureau. G Arias-Salgado: Grifols: Research Funding; Novo Nordisck, Novartis: Speakers Bureau. Rivas Pollmar: Novo Nordisck, Novartis: Speakers Bureau. Martin Salces: Novo Nordisck, Novartis: Speakers Bureau. Ghanima: Grifols: Consultancy, Honoraria; UCB: Consultancy, Honoraria; BMS: Honoraria, Research Funding; Sanofi: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Sobi, Pfizer: Consultancy, Honoraria, Research Funding; Argenx: Consultancy, Honoraria; Bayer: Consultancy, Honoraria, Research Funding; alpine: Consultancy, Honoraria; cellphire: Consultancy, Honoraria; hibio: Consultancy, Honoraria; Kedrion: Consultancy; Amgen: Consultancy, Honoraria. Jiménez-Yuste: CSL Behring: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; Novo Nordisk: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; BioMarin: Consultancy; Sanofi: Consultancy, Honoraria, Research Funding; Sobi: Consultancy, Honoraria, Research Funding; Grifols: Consultancy, Honoraria, Research Funding. Butta: Novo Nordisck, Novartis: Speakers Bureau; Takeda, Novo Nordisck: Research Funding.

*signifies non-member of ASH